Clinical Scorecard: A Novel Image Processing Method for Identifying Cardiotoxic Effects of Anthracyclines Through Myocardial Metabolic Activity Assessment in [18F]FDG PET/CT Scans

At a Glance

Key Highlights

• Cardiotoxicity is a major secondary effect of anthracycline chemotherapy, increasing risk of left ventricular systolic dysfunction and heart failure.
• Conventional echocardiography parameters (LVEF, GLS) have limitations in early detection due to measurement variability and limited specificity.
• [18F]FDG PET/CT imaging enables in-vivo assessment of myocardial glucose metabolism, potentially allowing earlier identification of cardiotoxicity through metabolic changes.

Guideline-Based Recommendations

Diagnosis

• Use echocardiography to assess LVEF, considering a decrease of 5% below 53% or 10% decrease as criteria for cardiotoxicity.
• Consider global longitudinal strain (GLS) as a supplementary parameter despite limited specificity.
• Employ a multimodal approach combining imaging modalities for cardiotoxicity detection during and after cancer treatment.

Management

• Monitor patients receiving anthracyclines closely for cardiac toxicity.
• Incorporate [18F]FDG PET/CT imaging to assess myocardial metabolic activity as an adjunct to echocardiography.

Monitoring & Follow-up

• Perform serial [18F]FDG PET/CT scans at staging, interim, and end-of-treatment to evaluate myocardial uptake patterns.
• Standardize patient preparation including fasting and hydration to reduce variability in myocardial glucose uptake.

Risks

• Variability in LVEF measurement by 2D echocardiography can be as high as 10%, limiting early detection.
• Myocardial glucose uptake is influenced by multiple factors (diet, blood glucose, insulin, age, fasting state, drugs), which may confound PET/CT interpretation.

Patient & Prescribing Data

Patients with Hodgkin and Non-Hodgkin lymphoma treated with anthracycline-containing chemotherapy regimens

Anthracycline chemotherapy is associated with increased myocardial [18F]FDG uptake indicative of early cardiotoxic metabolic changes before functional impairment.

Clinical Best Practices

• Ensure patient fasting for at least 6 hours prior to [18F]FDG injection and encourage hydration to optimize PET/CT imaging quality.
• Use image processing tools to filter PET images and accurately segment left ventricular myocardium for quantitative analysis.
• Orient left ventricle along standardized heart axes (HLA, VLA, SA) to enable reproducible myocardial uptake assessment.
• Apply quantitative parameters describing myocardial metabolism to differentiate physiological from pathological uptake patterns.
• Consider manual correction of left ventricle localization on PET/CT images to improve segmentation accuracy.

References

• Cancer therapy and cardiotoxicity overview
• Echocardiographic criteria for cardiotoxicity
• Use of [18F]FDG PET/CT in myocardial metabolic assessment
• Standardized heart axes for cardiac imaging
• Image filtering method for PET noise reduction